Imugene Limited (AU:IMU) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Imugene Limited has reported promising progress in its clinical trials, including three complete responses in its azer-cel Phase 1b trial for treating diffuse large B-cell lymphoma. The company has also received FDA Orphan Drug Designation for its VAXINIA treatment for bile tract cancer, with the first patient dosed in a Phase 1 trial in Melbourne. Imugene’s cash position stands strong at $53.3 million as of September 30, 2024.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.